http://openwetware.org/index.php?title=Lee:Publications&feed=atom&action=historyLee:Publications - Revision history2013-05-25T02:40:44ZRevision history for this page on the wikiMediaWiki 1.13.2http://openwetware.org/index.php?title=Lee:Publications&diff=697797&oldid=prevWooin Lee: /* 2013 */2013-05-13T12:47:42Z<p><span class="autocomment">2013</span></p>
<table style="background-color: white; color:black;">
<col class='diff-marker' />
<col class='diff-content' />
<col class='diff-marker' />
<col class='diff-content' />
<tr valign='top'>
<td colspan='2' style="background-color: white; color:black;">←Older revision</td>
<td colspan='2' style="background-color: white; color:black;">Revision as of 12:47, 13 May 2013</td>
</tr>
<tr><td colspan="2" class="diff-lineno">Line 6:</td>
<td colspan="2" class="diff-lineno">Line 6:</td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2013==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2013==</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Thakkar N, Kim K, Jang ER, Han S, Kim K, Kim D, Merchant N, Lockhart AC, Lee W. A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm. 2013;10(1):406-416. (PMID:23215050)</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Thakkar N, Kim K, Jang ER, Han S, Kim K, Kim D, Merchant N, Lockhart AC, Lee W. A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm. 2013;10(1):406-416. (PMID:23215050)</div></td></tr>
<tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div># Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des <del class="diffchange diffchange-inline">(</del>2013<del class="diffchange diffchange-inline">, in press</del>) (PMID: 23181576)</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div># Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des 2013<ins class="diffchange diffchange-inline">;19(2</ins>)<ins class="diffchange diffchange-inline">:4140-4151. </ins>(PMID: 23181576)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2012==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2012==</div></td></tr>
<!-- diff generator: internal 2013-05-25 02:40:44 -->
</table>Wooin Leehttp://openwetware.org/index.php?title=Lee:Publications&diff=673215&oldid=prevWooin Lee at 15:11, 5 February 20132013-02-05T15:11:00Z<p></p>
<table style="background-color: white; color:black;">
<col class='diff-marker' />
<col class='diff-content' />
<col class='diff-marker' />
<col class='diff-content' />
<tr valign='top'>
<td colspan='2' style="background-color: white; color:black;">←Older revision</td>
<td colspan='2' style="background-color: white; color:black;">Revision as of 15:11, 5 February 2013</td>
</tr>
<tr><td colspan="2" class="diff-lineno">Line 6:</td>
<td colspan="2" class="diff-lineno">Line 6:</td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2013==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2013==</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Thakkar N, Kim K, Jang ER, Han S, Kim K, Kim D, Merchant N, Lockhart AC, Lee W. A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm. 2013;10(1):406-416. (PMID:23215050)</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Thakkar N, Kim K, Jang ER, Han S, Kim K, Kim D, Merchant N, Lockhart AC, Lee W. A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm. 2013;10(1):406-416. (PMID:23215050)</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div><ins style="color: red; font-weight: bold; text-decoration: none;"># Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des (2013, in press) (PMID: 23181576)</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2012==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2012==</div></td></tr>
<tr><td colspan="2" class="diff-lineno">Line 12:</td>
<td colspan="2" class="diff-lineno">Line 13:</td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Ao L, Wu Y, Kim D, Jang ER, Kim K, Lee D, Kim KB, Lee W. Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib. Mol. Pharmaceutics 2012;9:2197−2205 (PMID: 22734651)</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Ao L, Wu Y, Kim D, Jang ER, Kim K, Lee D, Kim KB, Lee W. Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib. Mol. Pharmaceutics 2012;9:2197−2205 (PMID: 22734651)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Infante J, Keedy V, Jones S, Zamboni W, Chan E, Bendell J, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg M, Burris III H. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemo Pharmacol 2012 Nov;70(5):699-705 (PMID: 22941375).</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Infante J, Keedy V, Jones S, Zamboni W, Chan E, Bendell J, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg M, Burris III H. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemo Pharmacol 2012 Nov;70(5):699-705 (PMID: 22941375).</div></td></tr>
<tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div><del style="color: red; font-weight: bold; text-decoration: none;"># Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des (2012, in press) (PMID: 23181576)</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2011==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2011==</div></td></tr>
<!-- diff generator: internal 2013-05-25 02:40:44 -->
</table>Wooin Leehttp://openwetware.org/index.php?title=Lee:Publications&diff=665680&oldid=prevWooin Lee at 15:11, 7 January 20132013-01-07T15:11:53Z<p></p>
<table style="background-color: white; color:black;">
<col class='diff-marker' />
<col class='diff-content' />
<col class='diff-marker' />
<col class='diff-content' />
<tr valign='top'>
<td colspan='2' style="background-color: white; color:black;">←Older revision</td>
<td colspan='2' style="background-color: white; color:black;">Revision as of 15:11, 7 January 2013</td>
</tr>
<tr><td colspan="2" class="diff-lineno">Line 5:</td>
<td colspan="2" class="diff-lineno">Line 5:</td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2013==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2013==</div></td></tr>
<tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div> </div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div><ins class="diffchange diffchange-inline"># Thakkar N, Kim K, Jang ER, Han S, Kim K, Kim D, Merchant N, Lockhart AC, Lee W. A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm. 2013;10(1):406-416. (PMID:23215050)</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2012==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2012==</div></td></tr>
<tr><td colspan="2" class="diff-lineno">Line 13:</td>
<td colspan="2" class="diff-lineno">Line 13:</td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Infante J, Keedy V, Jones S, Zamboni W, Chan E, Bendell J, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg M, Burris III H. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemo Pharmacol 2012 Nov;70(5):699-705 (PMID: 22941375).</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Infante J, Keedy V, Jones S, Zamboni W, Chan E, Bendell J, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg M, Burris III H. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemo Pharmacol 2012 Nov;70(5):699-705 (PMID: 22941375).</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des (2012, in press) (PMID: 23181576)</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des (2012, in press) (PMID: 23181576)</div></td></tr>
<tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div><del style="color: red; font-weight: bold; text-decoration: none;"># Thakkar N, Kim K, Jang ER, Han S, Kim K, Kim D, Merchant N, Lockhart AC, Lee W. A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm. 2012 Dec 8. [Epub ahead of print] (PMID:23215050)</del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2011==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2011==</div></td></tr>
<!-- diff generator: internal 2013-05-25 02:40:44 -->
</table>Wooin Leehttp://openwetware.org/index.php?title=Lee:Publications&diff=663611&oldid=prevWooin Lee: /* 2012 */2012-12-13T20:17:06Z<p><span class="autocomment">2012</span></p>
<table style="background-color: white; color:black;">
<col class='diff-marker' />
<col class='diff-content' />
<col class='diff-marker' />
<col class='diff-content' />
<tr valign='top'>
<td colspan='2' style="background-color: white; color:black;">←Older revision</td>
<td colspan='2' style="background-color: white; color:black;">Revision as of 20:17, 13 December 2012</td>
</tr>
<tr><td colspan="2" class="diff-lineno">Line 13:</td>
<td colspan="2" class="diff-lineno">Line 13:</td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Infante J, Keedy V, Jones S, Zamboni W, Chan E, Bendell J, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg M, Burris III H. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemo Pharmacol 2012 Nov;70(5):699-705 (PMID: 22941375).</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Infante J, Keedy V, Jones S, Zamboni W, Chan E, Bendell J, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg M, Burris III H. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemo Pharmacol 2012 Nov;70(5):699-705 (PMID: 22941375).</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des (2012, in press) (PMID: 23181576)</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des (2012, in press) (PMID: 23181576)</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div><ins style="color: red; font-weight: bold; text-decoration: none;"># Thakkar N, Kim K, Jang ER, Han S, Kim K, Kim D, Merchant N, Lockhart AC, Lee W. A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm. 2012 Dec 8. [Epub ahead of print] (PMID:23215050)</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2011==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2011==</div></td></tr>
<!-- diff generator: internal 2013-05-25 02:40:44 -->
</table>Wooin Leehttp://openwetware.org/index.php?title=Lee:Publications&diff=661103&oldid=prevWooin Lee at 15:59, 29 November 20122012-11-29T15:59:51Z<p></p>
<table style="background-color: white; color:black;">
<col class='diff-marker' />
<col class='diff-content' />
<col class='diff-marker' />
<col class='diff-content' />
<tr valign='top'>
<td colspan='2' style="background-color: white; color:black;">←Older revision</td>
<td colspan='2' style="background-color: white; color:black;">Revision as of 15:59, 29 November 2012</td>
</tr>
<tr><td colspan="2" class="diff-lineno">Line 26:</td>
<td colspan="2" class="diff-lineno">Line 26:</td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2009==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2009==</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div><ins style="color: red; font-weight: bold; text-decoration: none;"></ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Lee W, Patel JH, Lockhart AC. Novel targets in esophageal and gastric cancer: beyond antiangiogenesis. Expert Opin Investig Drugs. 2009 Sep;18(9):1351-64. (pmid=19642951)</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Lee W, Patel JH, Lockhart AC. Novel targets in esophageal and gastric cancer: beyond antiangiogenesis. Expert Opin Investig Drugs. 2009 Sep;18(9):1351-64. (pmid=19642951)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2008==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2008==</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div><ins style="color: red; font-weight: bold; text-decoration: none;"></ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Lee W, Belkhiri A, Lockhart AC, Merchant N, Glaeser H, Harris EI, Washington MK, Brunt EM, Zaika A, Kim RB, El-Rifai W. Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res. 2008 Dec 15;68(24):10315-23. (pmid=19074900) </div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Lee W, Belkhiri A, Lockhart AC, Merchant N, Glaeser H, Harris EI, Washington MK, Brunt EM, Zaika A, Kim RB, El-Rifai W. Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res. 2008 Dec 15;68(24):10315-23. (pmid=19074900) </div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Lockhart AC, Harris E, LaFleur BJ, Merchant NB, Washington MK, Resnick MB, Yeatman TJ, Lee W. Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome. Clin Exp Gastroenterol:1-7(2008) (pmid=21677819)</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Lockhart AC, Harris E, LaFleur BJ, Merchant NB, Washington MK, Resnick MB, Yeatman TJ, Lee W. Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome. Clin Exp Gastroenterol:1-7(2008) (pmid=21677819)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Wade Calcutt M, Lee W, Puzanov I, Rothenberg ML, Hachey DL. Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. J Mass Spectrom. 2008 Jan;43(1):42-52. (pmid=17683023)</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Wade Calcutt M, Lee W, Puzanov I, Rothenberg ML, Hachey DL. Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. J Mass Spectrom. 2008 Jan;43(1):42-52. (pmid=17683023)</div></td></tr>
<tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div><del style="color: red; font-weight: bold; text-decoration: none;"></del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div><del style="color: red; font-weight: bold; text-decoration: none;"></del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==<2007==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==<2007==</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div><ins style="color: red; font-weight: bold; text-decoration: none;"></ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther. 2007 Mar;81(3):362-70. (pmid=17215845) </div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther. 2007 Mar;81(3):362-70. (pmid=17215845) </div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Marzolini C, Tirona RG, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake BF, Schuetz JD, Schuetz EG, Kim RB. A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol Endocrinol. 2007 Aug;21(8):1769-80. (pmid=17519356)</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Marzolini C, Tirona RG, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake BF, Schuetz JD, Schuetz EG, Kim RB. A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol Endocrinol. 2007 Aug;21(8):1769-80. (pmid=17519356)</div></td></tr>
<!-- diff generator: internal 2013-05-25 02:40:44 -->
</table>Wooin Leehttp://openwetware.org/index.php?title=Lee:Publications&diff=661102&oldid=prevWooin Lee at 15:58, 29 November 20122012-11-29T15:58:46Z<p></p>
<table style="background-color: white; color:black;">
<col class='diff-marker' />
<col class='diff-content' />
<col class='diff-marker' />
<col class='diff-content' />
<tr valign='top'>
<td colspan='2' style="background-color: white; color:black;">←Older revision</td>
<td colspan='2' style="background-color: white; color:black;">Revision as of 15:58, 29 November 2012</td>
</tr>
<tr><td colspan="2" class="diff-lineno">Line 3:</td>
<td colspan="2" class="diff-lineno">Line 3:</td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>|-valign="top"</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>|-valign="top"</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>|style="background:#ffffff"|</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>|style="background:#ffffff"|</div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div><ins style="color: red; font-weight: bold; text-decoration: none;"></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div><ins style="color: red; font-weight: bold; text-decoration: none;">==2013==</ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr>
<!-- diff generator: internal 2013-05-25 02:40:44 -->
</table>Wooin Leehttp://openwetware.org/index.php?title=Lee:Publications&diff=659825&oldid=prevWooin Lee: /* 2012 */2012-11-28T17:47:48Z<p><span class="autocomment">2012</span></p>
<table style="background-color: white; color:black;">
<col class='diff-marker' />
<col class='diff-content' />
<col class='diff-marker' />
<col class='diff-content' />
<tr valign='top'>
<td colspan='2' style="background-color: white; color:black;">←Older revision</td>
<td colspan='2' style="background-color: white; color:black;">Revision as of 17:47, 28 November 2012</td>
</tr>
<tr><td colspan="2" class="diff-lineno">Line 10:</td>
<td colspan="2" class="diff-lineno">Line 10:</td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Ao L, Wu Y, Kim D, Jang ER, Kim K, Lee D, Kim KB, Lee W. Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib. Mol. Pharmaceutics 2012;9:2197−2205 (PMID: 22734651)</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Ao L, Wu Y, Kim D, Jang ER, Kim K, Lee D, Kim KB, Lee W. Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib. Mol. Pharmaceutics 2012;9:2197−2205 (PMID: 22734651)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Infante J, Keedy V, Jones S, Zamboni W, Chan E, Bendell J, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg M, Burris III H. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemo Pharmacol 2012 Nov;70(5):699-705 (PMID: 22941375).</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Infante J, Keedy V, Jones S, Zamboni W, Chan E, Bendell J, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg M, Burris III H. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemo Pharmacol 2012 Nov;70(5):699-705 (PMID: 22941375).</div></td></tr>
<tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div># Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des (2012, in press)</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div># Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des (2012, in press<ins class="diffchange diffchange-inline">) (PMID: 23181576</ins>)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2011==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2011==</div></td></tr>
<!-- diff generator: internal 2013-05-25 02:40:44 -->
</table>Wooin Leehttp://openwetware.org/index.php?title=Lee:Publications&diff=653082&oldid=prevWooin Lee: /* 2012 */2012-11-10T20:03:37Z<p><span class="autocomment">2012</span></p>
<table style="background-color: white; color:black;">
<col class='diff-marker' />
<col class='diff-content' />
<col class='diff-marker' />
<col class='diff-content' />
<tr valign='top'>
<td colspan='2' style="background-color: white; color:black;">←Older revision</td>
<td colspan='2' style="background-color: white; color:black;">Revision as of 20:03, 10 November 2012</td>
</tr>
<tr><td colspan="2" class="diff-lineno">Line 9:</td>
<td colspan="2" class="diff-lineno">Line 9:</td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Kumar Sharma L, Lee N, Jang ER, Lei B, Zhan C-G, Lee W, Kim KB. Near-infrared fluorescent probe for LMP7: a chemical proteomics tool for immunoproteasome in living cells. Chembiochem. 2012;13(13):1899-903. (PMID:22807337)</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Kumar Sharma L, Lee N, Jang ER, Lei B, Zhan C-G, Lee W, Kim KB. Near-infrared fluorescent probe for LMP7: a chemical proteomics tool for immunoproteasome in living cells. Chembiochem. 2012;13(13):1899-903. (PMID:22807337)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Ao L, Wu Y, Kim D, Jang ER, Kim K, Lee D, Kim KB, Lee W. Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib. Mol. Pharmaceutics 2012;9:2197−2205 (PMID: 22734651)</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Ao L, Wu Y, Kim D, Jang ER, Kim K, Lee D, Kim KB, Lee W. Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib. Mol. Pharmaceutics 2012;9:2197−2205 (PMID: 22734651)</div></td></tr>
<tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div># Infante J, Keedy V, Jones S, Zamboni W, Chan E, Bendell J, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg M, Burris III H. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemo Pharmacol 2012 Nov;70(5):699-705.</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div># Infante J, Keedy V, Jones S, Zamboni W, Chan E, Bendell J, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg M, Burris III H. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemo Pharmacol 2012 Nov;70(5):699-705 <ins class="diffchange diffchange-inline">(PMID: 22941375)</ins>.</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des (2012, in press)</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des (2012, in press)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr>
<!-- diff generator: internal 2013-05-25 02:40:44 -->
</table>Wooin Leehttp://openwetware.org/index.php?title=Lee:Publications&diff=653081&oldid=prevWooin Lee: /* 2012 */2012-11-10T20:03:16Z<p><span class="autocomment">2012</span></p>
<table style="background-color: white; color:black;">
<col class='diff-marker' />
<col class='diff-content' />
<col class='diff-marker' />
<col class='diff-content' />
<tr valign='top'>
<td colspan='2' style="background-color: white; color:black;">←Older revision</td>
<td colspan='2' style="background-color: white; color:black;">Revision as of 20:03, 10 November 2012</td>
</tr>
<tr><td colspan="2" class="diff-lineno">Line 9:</td>
<td colspan="2" class="diff-lineno">Line 9:</td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Kumar Sharma L, Lee N, Jang ER, Lei B, Zhan C-G, Lee W, Kim KB. Near-infrared fluorescent probe for LMP7: a chemical proteomics tool for immunoproteasome in living cells. Chembiochem. 2012;13(13):1899-903. (PMID:22807337)</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Kumar Sharma L, Lee N, Jang ER, Lei B, Zhan C-G, Lee W, Kim KB. Near-infrared fluorescent probe for LMP7: a chemical proteomics tool for immunoproteasome in living cells. Chembiochem. 2012;13(13):1899-903. (PMID:22807337)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Ao L, Wu Y, Kim D, Jang ER, Kim K, Lee D, Kim KB, Lee W. Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib. Mol. Pharmaceutics 2012;9:2197−2205 (PMID: 22734651)</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Ao L, Wu Y, Kim D, Jang ER, Kim K, Lee D, Kim KB, Lee W. Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib. Mol. Pharmaceutics 2012;9:2197−2205 (PMID: 22734651)</div></td></tr>
<tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div># Infante J, Keedy V, Jones S, Zamboni W, Chan E, Bendell J, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg M, Burris III H. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemo Pharmacol <del class="diffchange diffchange-inline">(</del>2012<del class="diffchange diffchange-inline">, in press</del>).</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div># Infante J, Keedy V, Jones S, Zamboni W, Chan E, Bendell J, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg M, Burris III H. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemo Pharmacol 2012 <ins class="diffchange diffchange-inline">Nov;70(5</ins>)<ins class="diffchange diffchange-inline">:699-705</ins>.</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des (2012, in press)</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des (2012, in press)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"></td></tr>
<!-- diff generator: internal 2013-05-24 17:00:36 -->
<!-- diff cache key owwdb:diff:version:1.11a:oldid:653080:newid:653081 -->
</table>Wooin Leehttp://openwetware.org/index.php?title=Lee:Publications&diff=653080&oldid=prevWooin Lee: /* 2012 */2012-11-10T20:01:57Z<p><span class="autocomment">2012</span></p>
<table style="background-color: white; color:black;">
<col class='diff-marker' />
<col class='diff-content' />
<col class='diff-marker' />
<col class='diff-content' />
<tr valign='top'>
<td colspan='2' style="background-color: white; color:black;">←Older revision</td>
<td colspan='2' style="background-color: white; color:black;">Revision as of 20:01, 10 November 2012</td>
</tr>
<tr><td colspan="2" class="diff-lineno">Line 7:</td>
<td colspan="2" class="diff-lineno">Line 7:</td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2012==</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div>==2012==</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Jang ER, Lee N, Han S, Wu Y, Kumar Sharma L, Carmony KC, Marks J, Lee D, Ban J, Wehenkel M, Hong JT, Kim KB, Lee W. Revisiting the role of the immunoproteasome in the activation of the canonical NF-κB pathway. Mol Biosyst. 2012 Sep 31;8(9):2295-2302. (PMID:22722901)</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Jang ER, Lee N, Han S, Wu Y, Kumar Sharma L, Carmony KC, Marks J, Lee D, Ban J, Wehenkel M, Hong JT, Kim KB, Lee W. Revisiting the role of the immunoproteasome in the activation of the canonical NF-κB pathway. Mol Biosyst. 2012 Sep 31;8(9):2295-2302. (PMID:22722901)</div></td></tr>
<tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div># Kumar Sharma L, Lee N, Jang ER, Lei B, Zhan C-G, Lee W, Kim KB. Near-infrared fluorescent probe for LMP7: a chemical proteomics tool for immunoproteasome in living cells. Chembiochem. 2012 <del class="diffchange diffchange-inline">Sep 3</del>;13(13):1899-903. (PMID:22807337)</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div># Kumar Sharma L, Lee N, Jang ER, Lei B, Zhan C-G, Lee W, Kim KB. Near-infrared fluorescent probe for LMP7: a chemical proteomics tool for immunoproteasome in living cells. Chembiochem. 2012;13(13):1899-903. (PMID:22807337)</div></td></tr>
<tr><td class='diff-marker'>-</td><td style="background: #ffa; color:black; font-size: smaller;"><div># Ao L, Wu Y, Kim D, Jang ER, Kim K, Lee D, Kim KB, Lee W. Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib. Mol <del class="diffchange diffchange-inline">Pharm (</del>2012<del class="diffchange diffchange-inline">, in press, </del>PMID: 22734651)</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div># Ao L, Wu Y, Kim D, Jang ER, Kim K, Lee D, Kim KB, Lee W. Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib. Mol<ins class="diffchange diffchange-inline">. Pharmaceutics </ins>2012<ins class="diffchange diffchange-inline">;9:2197−2205 (</ins>PMID: 22734651)</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Infante J, Keedy V, Jones S, Zamboni W, Chan E, Bendell J, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg M, Burris III H. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemo Pharmacol (2012, in press).</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Infante J, Keedy V, Jones S, Zamboni W, Chan E, Bendell J, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg M, Burris III H. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemo Pharmacol (2012, in press).</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des (2012, in press)</div></td><td class='diff-marker'> </td><td style="background: #eee; color:black; font-size: smaller;"><div># Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the Immunoproteasome: Current Status and Future Directions. Curr Pharm Des (2012, in press)</div></td></tr>
<!-- diff generator: internal 2013-05-25 02:40:44 -->
</table>Wooin Lee